Few questions generate more confusion in the clinic and pharmacy space than the legality of compounded semaglutide and tirzepatide. The answer is not a simple yes or no — it depends on FDA shortage designations, the type of compounding entity involved, and compliance with specific regulatory conditions.

This post provides a clear, current overview of the legal framework as of 2026, what has changed, and what clinics and pharmacies need to do to stay on the right side of the law.

The legal basis for compounding semaglutide and tirzepatide rests on the drug shortage exception in federal compounding law.

Under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies and outsourcing facilities are permitted to compound drugs that appear on the FDA's drug shortage list. When a drug is in shortage, the FDA's normal restrictions on compounding copies of commercially available drugs are relaxed to allow compounding pharmacies to help meet patient demand.

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were both placed on the FDA's drug shortage list due to extraordinary demand that outpaced manufacturing capacity. During the shortage period, compounding of these drugs was explicitly permitted under federal law.

The FDA periodically reviews its drug shortage list and removes drugs when the shortage has been resolved. The removal of a drug from the shortage list has significant implications for compounding:

When a drug is removed from the shortage list, the shortage-based exception to compounding restrictions no longer applies. Compounding pharmacies and outsourcing facilities that were compounding the drug under the shortage exception must reassess whether they can continue to do so legally.

The FDA has taken enforcement action against compounders that continued to compound drugs after their removal from the shortage list without a valid legal basis for doing so.

The current status of semaglutide and tirzepatide on the FDA shortage list should be verified directly with the FDA's shortage database, as designations can change. As of the publication of this post, clinics and pharmacies should confirm current shortage status before sourcing or dispensing compounded preparations.

Even after a drug is removed from the shortage list, compounding may still be legally permissible under certain circumstances:

Patient-specific medical need (503A): A 503A pharmacy can compound a preparation for an individual patient if the prescriber documents a specific medical need that cannot be met by the commercially available product. For example, if a patient has an allergy to an excipient in the commercial product, or needs a different concentration or formulation, a 503A pharmacy may be able to compound a preparation for that patient.

Significant difference (503B): A 503B outsourcing facility may be able to compound a preparation that is "not essentially a copy" of the commercially available drug — for example, a preparation with a meaningfully different formulation, concentration, or delivery mechanism. The FDA has issued guidance on what constitutes a "significant difference" for this purpose.

State law: Some states have compounding laws that may provide additional permissions or restrictions beyond federal law. Clinics and pharmacies should be aware of their state's specific requirements.

The FDA has been increasingly active in enforcing compounding restrictions, particularly for high-profile drugs like semaglutide and tirzepatide. The agency has:

• Issued warning letters to compounders that continued to compound shortage drugs after removal from the shortage list
• Published guidance clarifying the conditions under which compounding of these drugs is and is not permissible
• Taken action against compounders that used unapproved salt forms of the active ingredient (e.g., semaglutide sodium or acetate rather than the base form used in FDA-approved products)

The FDA's position is that compounding of semaglutide and tirzepatide is only permissible when a valid legal basis exists — shortage exception, patient-specific medical need, or significant difference — and that compounders must be able to document that basis.

One specific area of FDA concern has been the use of salt forms of semaglutide and tirzepatide in compounded preparations. The FDA-approved products use specific forms of these molecules. Some compounders have used different salt forms (e.g., semaglutide sodium, semaglutide acetate) that are not the same as the active ingredient in the approved products.

The FDA has stated that compounding using these unapproved salt forms is not permissible, even during a shortage, because the salt form is not the same active ingredient as the approved drug. Clinics sourcing compounded GLP-1 preparations should ask their pharmacy partners specifically about the form of the active ingredient used and whether it matches the form in the FDA-approved product.

Given the evolving regulatory landscape, clinics that source compounded GLP-1 preparations should take the following steps:

1. Verify current shortage status: Check the FDA's drug shortage database for the current status of semaglutide and tirzepatide. This should be done regularly, as designations can change.

2. Confirm your pharmacy partner's legal basis: Ask your compounding pharmacy or 503B supplier what legal basis they are relying on to compound the preparations you source. They should be able to articulate a clear answer.

3. Verify the active ingredient form: Confirm that the preparations you source use the same form of the active ingredient as the FDA-approved product, not an unapproved salt form.

4. Maintain documentation: Keep records of the legal basis for sourcing compounded preparations, including shortage list status at the time of ordering and any patient-specific medical need documentation.

5. Consult regulatory counsel: If you have questions about the legality of specific sourcing arrangements, consult with a regulatory attorney who specializes in pharmaceutical compounding law.

1. Federal Food, Drug, and Cosmetic Act, Section 503A (21 U.S.C. § 353a) — Pharmacy Compounding.
2. Federal Food, Drug, and Cosmetic Act, Section 503B (21 U.S.C. § 353b) — Outsourcing Facilities.
3. U.S. Food and Drug Administration. Drug Shortage Database. FDA, accessed 2026.
4. U.S. Food and Drug Administration. Guidance for Industry: Compounding of Certain Drug Products Under Sections 503A and 503B of the FD&C Act. FDA, 2023.
5. U.S. Food and Drug Administration. FDA Takes Action Against Compounders of Semaglutide and Tirzepatide. FDA press releases, 2024–2025.
6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, updated 2024.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about the current regulatory landscape? Use the Get Connected form to reach our team.